SEC Comment Letter 0000000000-24-009798 to Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936) (CYTOF)
Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936)
Date: Aug. 28, 2024 · CIK: 0001601936 · Accession: 0000000000-24-009798
AI Filing Summary & Sentiment
File numbers found in text: 333-281724
Letter
August 28, 2024 Thomas Meyer Chief Executive Officer Altamira Therapeutics Ltd. 254 Chapman Rd, Ste 208 #15392 Newark, DE 19702 Re:Altamira Therapeutics Ltd. Registration Statement on Form F-1 Filed August 22, 2024 File No. 333-281724 Dear Thomas Meyer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Mike Bradshaw, Esq.
Show Raw Text
August 28, 2024
Thomas Meyer
Chief Executive Officer
Altamira Therapeutics Ltd.
254 Chapman Rd, Ste 208 #15392
Newark, DE 19702
Re:Altamira Therapeutics Ltd.
Registration Statement on Form F-1
Filed August 22, 2024
File No. 333-281724
Dear Thomas Meyer:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Mike Bradshaw, Esq.